What we expect to see for aggressive lymphoma at the American Society of Hematology meeting in December is probably ...

But in findings presented at the American College of Allergy, Asthma and Immunology (ACAAI) meeting in Orlando, the novel ...

Noncovalent Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib and chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel have gained FDA approval for double-refractory chronic ...

Panelists discuss how emerging therapies like menin inhibitors show promise based on strong preclinical data and clinical responses, while CD47 inhibitors have faced setbacks in phase 3 trials, with ...

Those are the odds of an unpublished author convincing a literary agent to represent your novel, according to Mark Malatesta at Literary-Agents.com. “The best book agents can get as many as 1,500 ...

Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice Classic Hodgkin lymphoma (cHL) is highly ...

Oral induction therapy with obefazimod (Abivax) for 8 weeks led to clinically meaningful improvements across all efficacy endpoints in a highly refractory population of patients with moderately to ...

Omar El Akkad’s “One Day, Everyone Will Have Always Been Against This” criticizes Western indifference to civilian suffering ...